Cotter C S, Singleton G T, Corman L C
Department of Otolaryngology, University of Florida, Gainesville.
Laryngoscope. 1994 Oct;104(10):1235-9. doi: 10.1288/00005537-199410000-00009.
Human parvovirus B19 (HP-B19), the etiologic agent of the common childhood illness erythema infectiosum, has been implicated in systemic immune disorders. Patients presenting with sensorineural hearing loss and/or dizziness, not readily categorized, were evaluated for immune-mediated inner ear disease. Appropriate serologic studies including parvovirus B19 antibody titers were conducted. Thirty patients with suspected immune-mediated inner ear disease were treated with corticosteroid trial for 5 to 7 days, then reexamined with repeat audiogram and/or vestibular testing. Seventeen patients with clinical response were treated with long-term corticosteroids and cyclophosphamide. Six patients had positive HP-B19 immunoglobulin M (IgM) titers and 8 patients had positive parvovirus immunoglobulin G (IgG) titers. All 14 patients responded to therapy. Parvovirus B19, therefore, is a possible etiology of immune-mediated inner ear disease.
人细小病毒B19（HP - B19）是儿童常见疾病传染性红斑的病原体，与全身性免疫疾病有关。对出现感音神经性听力损失和/或头晕且病因难以明确分类的患者进行了免疫介导性内耳疾病评估。进行了包括细小病毒B19抗体滴度在内的适当血清学研究。30例疑似免疫介导性内耳疾病的患者接受了5至7天的皮质类固醇试验性治疗，然后通过重复听力图和/或前庭测试进行复查。17例有临床反应的患者接受了长期皮质类固醇和环磷酰胺治疗。6例患者的HP - B19免疫球蛋白M（IgM）滴度呈阳性，8例患者的细小病毒免疫球蛋白G（IgG）滴度呈阳性。所有14例患者对治疗均有反应。因此，细小病毒B19是免疫介导性内耳疾病的一种可能病因。
